Anti-Human EGFR (Clone EGFR.1) – Purified in vivo PLATINUM™ Functional Grade
Anti-Human EGFR (Clone EGFR.1) – Purified in vivo PLATINUM™ Functional Grade
Product No.: E337
Clone EGFR.1 Target EGFR Formats AvailableView All Product Type Monoclonal Antibody Alternate Names ERBB, ERBB1, mENA Isotype Mouse IgG2b κ Applications IHC , WB |
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Recommended Isotype Controls Recommended Dilution Buffer Immunogen A431 cultured cells Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2830095 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone EGFR.1 recognizes the human EGFR. Background EGFR is a 170 kD transmembrane glycoprotein that is part of the ErbB family of receptors within the protein kinase superfamily. EGFR is one of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). EGFR is essential for various processes including controlling cell growth and differentiation and ductal development of the mammary glands. Ligand binding induces dimerization and autophosphorylation. It consists of a glycosylated extracellular domain which binds to EGF and an intracellular domain with tyrosine-kinase activity necessary for signal transduction. TGFα, vaccinia virus growth factor, and related growth factors can also bind to and signal through EGFR. Abnormal EGFR signaling has been implicated in inflammatory diseases such as psoriasis, eczema and atherosclerosis. Alzheimer's disease is linked with poor signaling of the EGFR and other receptor tyrosine kinases. Furthermore, over-expression of the EGFR is linked with the growth of various tumors. EGFR has been identified as an oncogene, a gene which in certain circumstances can transform a cell into a tumor cell, which has led to the therapeutic development of anticancer EGFR inhibitors. EGFR is a well-established target for both mAbs and specific tyrosine kinase inhibitors. Ligand/Receptor Members of the epidermal growth factor (EGF) family such as EGF, TGF-α, amphiregulin, betacellulin, heparin-binding EGF-like growth factor, GP30 and vaccinia virus growth factor PubMed NCBI Gene Bank ID UniProt.org Research Area Cell Biology . Signal Transduction Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone EGFR.1 is an antibody that specifically targets human EGFR, not mouse EGFR, and its in vivo use in mice is generally limited to models where human EGFR is present, such as xenografts or transgenic mice expressing human EGFR. Key in vivo applications of clone EGFR.1 in mice include:
EGFR.1 is not suitable for studies targeting mouse EGFR in standard immunocompetent mice because it lacks cross-reactivity with murine EGFR. There is no evidence in the literature for its use as a therapeutic antibody in mice outside of humanized or xenograft models. For applications in endogenous mouse EGFR, other antibodies such as those specifically developed against mouse EGFR should be used. Summary Table: In Vivo Uses of Clone EGFR.1 in Mice
In summary, clone EGFR.1’s in vivo use in mice is largely restricted to imaging or functional studies in models expressing human EGFR; it is not effective for studies involving endogenous mouse EGFR. In the context of EGFR (Epidermal Growth Factor Receptor) research, several antibodies and proteins are commonly used alongside EGFR.1: Monoclonal Antibodies Targeting EGFR
Other Proteins and Antibodies
These antibodies and proteins are often used in combination or individually to target EGFR in various cancer therapies, offering a range of treatment options depending on the specific cancer type and patient profile. Key Findings on Clone EGFR.1 in the Scientific LiteratureThere is no direct scientific literature on "clone EGFR.1" as a specific biological or cancer research topic in the provided search results—rather, the term "clone" in your query may refer to either (a) a monoclonal antibody clone (such as "EGFR.1" used for laboratory detection), or (b) the concept of tumor cell clones with altered EGFR status (e.g., EGFR mutations, amplification, or clonal evolution). I will summarize key findings from both relevant contexts. Monoclonal Antibody EGFR.1The term "EGFR.1" appears as a monoclonal antibody clone engineered to target the human EGFR protein, used in laboratory research and diagnostics. For example, Leinco Technologies markets an "Anti-Human EGFR, Clone EGFR.1" for in vivo and in vitro applications. However, the provided scientific literature does not describe experimental findings specifically related to the use or effects of this clone in research, but it is evident that monoclonal antibodies like EGFR.1 (and, e.g., "EGFR1" clone ab30 from Abcam) are used to detect EGFR protein expression, binding specifically to the external domain of EGFR without affecting tyrosine kinase activity. EGFR Clonal Evolution and Tumor BiologyIntratumor Heterogeneity of EGFR Expression EGFR Copy Number Gain Clonal Evolution Under Treatment Pressure Acquired Resistance and Clonal Decay Summary Table: Key EGFR Clonal Findings
Clinical and Translational Implications
ConclusionWhile there is no direct citation of findings from "clone EGFR.1" as a research model in the provided literature, the broader context of EGFR clonal biology in cancer reveals significant insights into tumor evolution, therapeutic resistance, and the importance of genomic profiling for personalized oncology. Monoclonal antibodies like EGFR.1 are tools for research and diagnostics, but the most impactful scientific findings concern the behavior of tumor cell clones with altered EGFR status under selective pressure from targeted therapies. The dosing regimens for clone EGFR.1, an anti-human EGFR monoclonal antibody, are generally based on standard antibody practices in mouse models. While specific details on variability across different models are not provided in the available literature, typical dosing for such antibodies often ranges from 5 to 20 mg/kg and can be administered once or twice weekly. In general, dosing regimens for EGFR inhibitors can vary based on factors like the specific mutation type, the model's sensitivity to the drug, and the desired clinical outcome. For instance, in some studies involving EGFR mutant mouse models, other EGFR inhibitors are dosed at 20 to 100 mg/kg daily to achieve significant tumor growth inhibition. However, direct comparisons for clone EGFR.1 across various mouse models are not detailed in the provided sources. References & Citations1. Berger, SM. et al. (1987) J. of Pathology 152:297 2. Downward, J. et al. (1984) Nature 311:483 3. Gullick, WJ. et al. (1985) EMBO J. 4:2869 4. Gullick, WJ. et al. (1986) Cancer Research 46:285 5. Gullick, WJ. et al. (1991) Br. Med. Bulletin 47:87 Technical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
E333 | |
E325 | |
E326 | |
E327 | |
E329 | |
E331 | |
E336 | |
E101 | |
E337 | |
E100 |
